Sanofi Pasteur: Announces Dengue Vaccine available by 2H, 2015

The world’s first dengue vaccine is in production, and could be available as early as the second half of 2015, says French drug maker Sanofi Pasteur.

It said in a statement that a second late-stage clinical study showed 95.5% protection against severe dengue and a reduction of hospitalisation risk by 80.3%.

Sanofi Pasteur, the vaccines division of multinational pharmaceutical company Sanofi, announced the detailed results of the final landmark Phase III clinical efficacy study in Latin America in The New England Journal of Medicine.

The company said the overall efficacy against any symptomatic dengue disease was 60.8% in children and adolescents nine to 16 years old who received three doses of the vaccine.

The study was conducted on over 31,000 participants across 10 endemic countries in Latin America and Asia, including Malaysia.

Dengue is endemic in over 100 countries, making it a threat to nearly half of the world’s population. One person is hospitalised for dengue every single minute.

Sanofi has spent the last 20 years developing the vaccine that is several years ahead of potential competitors.

/Bernama 04-11-2014

Disclaimer: Views or opinions expressed are solely those of the Author and should be used with discretion. The Author shall not be held liable for any acts or omissions arising from the use of the information. The user will be personally liable for any damages or other liability arising hereof.